| Dr David Romesh Persaud, MD | |
|
772 Maddox Dr, Ste. 122, East Ellijay, GA 30540-8196 | |
| (706) 635-6898 | |
| (706) 635-6888 |
| Full Name | Dr David Romesh Persaud |
|---|---|
| Gender | Male |
| Speciality | Family Medicine - Geriatric Medicine |
| Location | 772 Maddox Dr, East Ellijay, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609087527 | NPI | - | NPPES |
| 003143127A | Medicaid | GA | |
| 202I087630 | Other | GA | MEDICARE PTAN |
| 1035769 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QG0300X | Family Medicine - Geriatric Medicine | 70703 (Georgia) | Primary |
| Entity Name | Gulfview Medical Institute Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851680789 PECOS PAC ID: 9335327139 Enrollment ID: O20110627000398 |
News Archive
St. John Hospital and Medical Center in Detroit and Avinger, Inc., a medical device company focused on the development of innovative devices to combat peripheral artery disease, announced today the enrollment of the first patient in the CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial.
In new findings published online March 18, 2021 in the journal Cancer Cell, an international team of researchers, led by scientists at University of California San Diego School of Medicine and Moores Cancer Center, describe how pancreatic cancer cells use an alternative method to find necessary nutrients, defying current therapies, to help them grow and spread.
Glaucoma is one of the leading causes of blindness worldwide. A major risk factor for glaucoma is elevated eye pressure due to poor drainage of aqueous humor, the fluid that provides nutrients to the eye.
Fetuses with congenital malformations can be helped by surgical intervention while still in the womb. The potential of intrauterine surgery to improve their chances of survival is described by Anke Diemert and her co-authors in the latest issue of Deutsches Ärzteblatt International.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Romesh Persaud, MD 165 Blue Ridge Overlook, Blue Ridge, GA 30513-4431 Ph: (706) 946-5600 | Dr David Romesh Persaud, MD 772 Maddox Dr, Ste. 122, East Ellijay, GA 30540-8196 Ph: (706) 635-6898 |
News Archive
St. John Hospital and Medical Center in Detroit and Avinger, Inc., a medical device company focused on the development of innovative devices to combat peripheral artery disease, announced today the enrollment of the first patient in the CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial.
In new findings published online March 18, 2021 in the journal Cancer Cell, an international team of researchers, led by scientists at University of California San Diego School of Medicine and Moores Cancer Center, describe how pancreatic cancer cells use an alternative method to find necessary nutrients, defying current therapies, to help them grow and spread.
Glaucoma is one of the leading causes of blindness worldwide. A major risk factor for glaucoma is elevated eye pressure due to poor drainage of aqueous humor, the fluid that provides nutrients to the eye.
Fetuses with congenital malformations can be helped by surgical intervention while still in the womb. The potential of intrauterine surgery to improve their chances of survival is described by Anke Diemert and her co-authors in the latest issue of Deutsches Ärzteblatt International.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.
› Verified 1 days ago
Daniela Maria Rojas-molina, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 772 Maddox Dr Ste 122, East Ellijay, GA 30540 Phone: 706-635-6898 Fax: 706-356-6885 | |
Anne Berry Todd, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 433 Highland Pkwy Ste 101, East Ellijay, GA 30540 Phone: 706-698-8400 Fax: 706-698-8401 | |
Dr. Islam G Eltarawy, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 97 Hefner St, Suite 202, East Ellijay, GA 30540 Phone: 706-635-1400 Fax: 706-635-1411 | |
Dr. Thomas A Nguyen, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 97 Hefner St Ste 202, East Ellijay, GA 30540 Phone: 706-635-5177 Fax: 706-635-5171 | |
Dr. Asim Kidwai, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 97 Hefner St, Suite 202, East Ellijay, GA 30540 Phone: 706-635-1400 Fax: 706-635-1411 | |
Susan J Smith, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 772 Maddox Dr Ste 122, East Ellijay, GA 30540 Phone: 706-635-6898 Fax: 706-635-6885 |